mTOR 在乳腺癌患者中的表达及意义

目的：探讨mTOR、p-mTOR在乳腺癌中的表达及临床意义，为乳腺癌的临床治疗提供理论依据。方法应用免疫组织化学SP方法及Western印迹方法研究90例乳腺组织中mTOR、p-mTOR的表达，其中乳腺癌组织50例（乳腺导管原位癌5例、浸润性特殊乳腺癌10例，浸润性小叶癌14例，浸润性导管癌21例）；乳腺良性病变40例。结果 mTOR在乳腺癌的阳性表达率为64．00％（32／50），与乳腺良性病变组织相比无统计学差异（χ2＝0．128，P＞0．05），但与乳腺癌旁组织比较差异显著（χ2＝7．758，P＜0．05）；p-mTOR在乳腺癌的阳性表达率为72．00％（36／50），与癌旁组织和乳腺良性病变相比均有显著性差异（χ2值分别为11．055、3．927，均P＜0．05）。此外，mTOR、p-mTOR的表达与乳腺癌淋巴结转移有关（χ2值分别为4．271、6．913，P＜0．05），与患者年龄、肿瘤大小、临床分期、组织学类型无关（χ2值分别为0．298、0．613、0．539、0．094，0．010、0．105、2．797、0．206，均P＞0．05）。结论 mTOR、p-mTOR在乳腺癌中表达增加可能与乳腺癌发生及乳腺癌淋巴结转移有关，提示其可能在乳腺癌发生、发展中起促进作用。

Expression and clinical significance of mTOR in breast cancer

Objective To study the expression and significance of mTOR and p-mTOR in primary breast carcer so as to provide theoretical basis for clinical treatment of breast cancer .Methods The expressions of mTOR and p-mTOR were studied in breast carcer samples by immunohistochemical (IHC) analysis and Western blot .Results The positive expression rate of mTOR was 64.00% (32/50) in breast cancer tissues, which was not different from that in breast benign lesions (χ2 =0.128,P>0.05) but significantly different from that in breast cancer adjacent tissues (χ2 =7.758, P<0.05).The positive expression rate of p-mTOR was 72.00% (36/50) in breast cancer tissues, and there was significant difference from that in breast benign lesions and adjacent cancer tissues (χ2 value was 11.055 and 3.927, respectively, both P<0.05).The expressions of mTOR and p-mTOR were correlated with the metastasis of lymph node (χ2 value was 4.271 and 6.913, respectively, both P <0.05 ) but not correlated with patients'age, tumor size, different clinical type and histological type (χ2 value was 0.298, 0.613, 0.539, 0.094, 0.010, 0.105, 2.797 and 0.206,respectively, all P>0.05).Conclusion Higher expressions of mTOR and p-mTOR may be correlated with breast cancer and metastasis of lymph node , indicating their role in pathogenesis and development of breast cancer .